LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : SpringWorks
Shots: Dana-Farber to receive up front & will be eligible to receive development and commercial milestones along with royalties on product sales SpringWorks has also entered into an SRA with […]readmore
Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore
Shots: SpringWorks and Dana-Farber collaborated to evaluate nirogacestat with anti-B-cell maturation antigen (BCMA) agents in multiple preclinical multiple myeloma models SpringWorks will fund the work and will retain an option […]readmore
Vertex and CRISPR Therapeutics Present New Data of CTX001 from 22 Patients with TDT and SCD at EMA 2021 Published: June 11, 2021 | Tags: Vertex, CRISPR Therapeutics, CTX001, TDT, […]readmore
Shots: The companies will evaluate SpringWorks’ nirogacestat (GSI) + Seagen’s SEA-BCMA (Ab targeting BCMA) in patients with RRMM. The companies anticipate commencement of the study in H2’21 Seagen to sponsor […]readmore
Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron Presents Results of Sotatercept in […]readmore
Shots: The first patient has been dosed in P-Ib trial evaluating SpringWorks’ Nirogacestat (GSI) + Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. Janssen assumes all […]readmore
Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease Published: Oct 9, 2020 | Tags: Alpha-1 Antitrypsin-Associated Liver Disease, Arrowhead, Collaborates, Commercialize. ARO-AAT, Develop, Takeda, […]readmore
Shots: The agreement involves assessing safety, efficacy and tolerability of BeiGene’s RAFi dimer, lifirafenib (BGB-283) and SpringWorks’ MEKi (PD-0325901), in patients with advanced solid tumours BeiGene will look forward for […]readmore